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The COVID-19 global pandemic, infecting 
over 3.5 million people and killing over a quarter of 
a million in the first 4 months of 2020 [1], required 
physicians all over the world to suddenly face a 
completely new nosological identity, with unknown 
characteristics and clinical challenges. 
Italy was the first Western country hardly hit 
by the epidemic, with the region of Milan being in 
the epicenter of the phenomenon. San Raffaele Sci-
entific Institute was one of the first centers to 
organize an all-out response to the virus [2]. Our 
multidisciplinary scientific team was the first to 
hypothesize and publish a theory about acute res-
piratory distress syndrome (ARDS) pathogenesis in 
COVID-19, accounting for the peculiar clinical and 
radiological presentation  [3]. The syndrome was 
called MicroCLOTS (microvascular COVID-19 lung 
vessels obstructive thromboinflammatory syn-
drome): the replication of SARS-CoV-2 in cells 
expressing the surface receptor angiotensin-con-
verting enzyme 2 (ACE2) may stimulate innate 
immune responses and complement activation, 
causing a massive local release of pro-inflammato-
ry cytokines ultimately resulting in severe tissue 
injury and microvascular thrombosis.  
As cells expressing ACE2 include lung epithe-
lial cells, but also arterial and venous endothelial 
cells and arterial smooth muscle cells of multiple 
organs [4], MicroCLOTS theory may explain also 
the high incidence of both venous and arterial 
thromboembolism in COVID-19 patients. In fact, 
up to 1/3 of critically ill patients with COVID-19 
appears to develop thrombotic complications [5] in 
spite of adequate thromboprophylaxis protocols. 
Thromboembolic complication ranged from deep 
venous thrombosis to ischemic stroke to the detec-
tion of thrombi in the lungs. 
The presence of MicroCLOTS in the lungs may 
also explain the inefficacy or even the harm of high 
PEEP ventilation and excessive negative fluid bal-
ance, which are constricting pulmonary arterioles 
already partially obstructed by clots 
Renal involvement also has a major role in 
COVID19: preliminary reports from Wuhan, China 
indicate that acute kidney injury occurred in 25 to 
29 percent of critically ill patients [6, 7]. While West-
ern world data on this topic are still lacking, the 
issue is being investigated [8]: autopsies reported 
peritubular erythrocyte aggregation and glomeru-
lar fibrin thrombi with ischemic collapse in kidneys 
of deceased COVID19 patients [9], possibly imply-
ing a similar etiology to pulmonary MicroCLOTS. 
Managing a wide range of COVID-19 patients 
over the last two months, it appears we’ve being two 
different entities: an inflammatory phase, which 
responds well when targeting interleukins [10, 11] 
or complement [12] and a thrombotic phase which 
seems to respond well to thromboprophylaxis with 
low molecular weight heparin started early (at home 
or at hospital arrival) and to full anticoagulation in 
intensive care unit patients  [13] and in selected 
patients in the main wards.
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